Immutep Ltd has released a press release.
Appendix 4E & 2026 Full Year Statutory Accounts
Earlier from Immutep
- Immutep Quarterly Activities Report Q4 FY26
- Immutep: Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
- Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
- Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004